The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2015

Filed:

Dec. 23, 2008
Applicants:

Gregor Schulz, Umkirch, DE;

Christoph Bruecher, Eschborn, DE;

Frank Osterroth, Dietzenbach, DE;

Steffen Zeng, Muenster, DE;

Christoph Uherek, Seligenstadt, DE;

Silke Aigner, Frankenthal, DE;

Benjamin Daelken, Frankfurt am Main, DE;

Markus Ruehle, Wiesbaden, DE;

Elmar Kraus, Bad Vilbel, DE;

Inventors:

Gregor Schulz, Umkirch, DE;

Christoph Bruecher, Eschborn, DE;

Frank Osterroth, Dietzenbach, DE;

Steffen Zeng, Muenster, DE;

Christoph Uherek, Seligenstadt, DE;

Silke Aigner, Frankenthal, DE;

Benjamin Daelken, Frankfurt am Main, DE;

Markus Ruehle, Wiesbaden, DE;

Elmar Kraus, Bad Vilbel, DE;

Assignees:

Biotest AG, Dreieich, DE;

Immunogen, Inc., Waltham, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/48 (2006.01); C07K 16/28 (2006.01); B82Y 5/00 (2011.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 47/48561 (2013.01); A61K 2039/505 (2013.01); A61K 39/39558 (2013.01); C07K 2317/34 (2013.01); B82Y 5/00 (2013.01); A61K 47/48723 (2013.01); C07K 2317/24 (2013.01); A61K 47/48569 (2013.01);
Abstract

Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and kits allow appropriate sequestration of non-target cells while maintaining a high degree of effectiveness of the immunoconjugates against target cells.


Find Patent Forward Citations

Loading…